Generex Biotechnology Corporation (NASDAQ: GNBT), a leader in the area of buccal drug delivery, today announced the successful completion of the delivery and installation of a turnkey Generex Oral-lyn™ filling operation at the facilities of PharmaBrand, S.A. (www.pharmabrand.com.ec) in Quito, Ecuador. PharmaBrand is the Company's joint venture partner for the commercialization of Generex Oral-lyn in Latin America. Generex Oral-lyn is the Company's proprietary oral insulin spray product which is designed to replace prandial subcutaneous injections of insulin by delivering insulin into the human body via a spray applied to the buccal mucosa using the Company's proprietary RapidMist™ device.
